These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 25131)

  • 1. Comparison of enzymatic activities of two deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.
    Meyers MB; Kreis W
    Cancer Res; 1978 Apr; 38(4):1105-12. PubMed ID: 25131
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural comparison of deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.
    Meyers MB; Kreis W
    Cancer Res; 1978 Apr; 38(4):1099-104. PubMed ID: 639039
    [No Abstract]   [Full Text] [Related]  

  • 3. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
    Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R
    Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of protein and DNA in P815 cells sensitive and resistant to 1- -D-arabinofuranosylcytosine.
    Kreis W; Drahovsky D; Borberg H
    Cancer Res; 1972 Apr; 32(4):696-701. PubMed ID: 4622581
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated level of enzymatic DNA methylation in cells treated with 1-beta-D-arabinofuranosylcytosine.
    Boehm TL; Drahovsky D
    Cancer Res; 1982 Apr; 42(4):1537-40. PubMed ID: 7060025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of selected substrates by semipurified cytoplasmic kinases of three P815 murine leukemias exhibiting collateral sensitivity (P815/TG), sensitivity (P815) or resistance (P815/ARA-C) to 1-beta-D-arabinofuranosylcytosine.
    Kreis W; Graham J; Damin LA
    Biochem Pharmacol; 1982 Dec; 31(23):3831-7. PubMed ID: 6297500
    [No Abstract]   [Full Text] [Related]  

  • 9. Kinase and deaminase activity in a variety of subcutaneous mouse tumors.
    Furner RL; Mellett LB
    Cancer Res; 1975 Jul; 35(7):1799-803. PubMed ID: 165884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
    Furner RL; Mellett LB; Herren TC
    J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation.
    Durham JP; Ives DH
    Mol Pharmacol; 1969 Jul; 5(4):358-75. PubMed ID: 4308509
    [No Abstract]   [Full Text] [Related]  

  • 12. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.
    Wan CW; Mak TW
    Cancer Res; 1978 Sep; 38(9):2768-72. PubMed ID: 679182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic disposition of cytosine arabinoside and its derivatives in man.
    Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
    Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular phosphorylation of 1-beta-D-arabinofuranosylcytosine 5-azacytidine with intact fibrosarcoma and leukemic cells.
    Lee T; Karon M; Monparler RL
    Cancer Res; 1975 Sep; 35(9):2506-10. PubMed ID: 50132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW; Cheng YC; Schabel FM; Montgomery JA
    Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB; Tong WP; Chou TC
    Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
    Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
    Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
    Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow microfluorimetric analysis of sensitive and resistant leukemia L1210 following 1-beta-D-arabinofuranosylcytosine in vivo.
    Alabaster O; Bunnag B
    Cancer Res; 1976 Aug; 36(8):2744-9. PubMed ID: 1277184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.